<DOC>
	<DOC>NCT01670058</DOC>
	<brief_summary>- The prevalence of Belatacept use - The characteristics of Belatacept users and the temporal trends in these characteristics - Characteristics of adult kidney-only transplant recipients who are treated with Belatacept vs. who are treated with Calcineurin inhibitors (CNI)-based regimens at the time of transplantation, and the temporal trends in these characteristics during 7 years post approval of Belatacept.</brief_summary>
	<brief_title>Pattern Of Use Of Belatacept In US Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. The cohort for the analyses of all transplants includes all organ transplant recipients who are reported with Belatacept at transplant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>